BrainsWay Ltd. (TLV:BWAY)
3,458.00
-168.00 (-4.63%)
Oct 23, 2026, 1:44 PM IDT
BrainsWay Revenue
BrainsWay had revenue of $17.11M USD in the quarter ending June 30, 2026, with 35.43% growth. This brings the company's total for the last twelve months to $60.70M, up 31.71% year-over-year. In the year 2025, BrainsWay had annual revenue of $52.23M with 27.33% growth. That makes BrainsWay the 26,827th largest company in the world by revenue and 291st in Israel.
Revenue (ttm)
$60.70M
Revenue Growth
+31.71%
P/S Ratio
7.70
Revenue / Employee
$470.50K
Employees
129
Market Cap
1.39B ILS
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full BrainsWay breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 52.23M | 11.21M | 27.33% |
| Dec 31, 2024 | 41.02M | 9.23M | 29.04% |
| Dec 31, 2023 | 31.79M | 4.61M | 16.96% |
| Dec 31, 2022 | 27.18M | -2.48M | -8.36% |
| Dec 31, 2021 | 29.66M | 7.60M | 34.46% |
| Dec 31, 2020 | 22.06M | -1.04M | -4.52% |
| Dec 31, 2019 | 23.10M | 6.70M | 40.89% |
| Dec 31, 2018 | 16.40M | 5.25M | 47.12% |
| Dec 31, 2017 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Danel (Adir Yeoshua) | 2.98B |
| Amal Holdings A.D. | 2.25B |
| Novolog (Pharm-Up 1966) | 1.81B |
| Ilex Medical | 885.35M |
| Kamada | 571.54M |
| Rafa Laboratories | 459.86M |
| SofWave Medical | 310.85M |
| InterCure | 270.20M |
BrainsWay News
- 4 days ago - BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group - GlobeNewsWire
- 10 days ago - Brainsway reports rise in Swift Accelerated Deep TMS protocol coverage - TheFly
- 10 days ago - BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives - GlobeNewsWire
- 6 weeks ago - Brainsway publishes results from pilot study - TheFly
- 6 weeks ago - BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™ - GlobeNewsWire
- 7 weeks ago - Brainsway price target raised to $19 from $17 at H.C. Wainwright - TheFly
- 2 months ago - Brainsway reports Q2 EPS 7c, consensus 7c - TheFly
- 2 months ago - Brainsway raises FY26 revenue view to $68M-$70M from $66M-$68M - TheFly